PDF icon Download PDF
Open Access
CC BY 4.0 · World J Nucl Med
DOI: 10.1055/s-0045-1810008
Case Report

99mTc-MAA Scintigraphy for Assessing Hepatic Arterial Infusion Pump: The Rate Being a Snare

Adithya Hari 
1   Molecular Imaging and Therapy, Memorial Sloan Kettering Cancer Center, New York City, New York, United States
,
Justin Jacobs
2   Nuclear Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, United States
,
Shalini Chhabra
2   Nuclear Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, United States
,
Ravinder K. Grewal
2   Nuclear Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, United States
› Author Affiliations
Funding This work was supported in part by NIH/NCI Cancer Center Support Grant P30 ‎CA‎008748.
› Further Information
Also available ateRefMedOne
  Permissions and Reprints
Preview

Abstract

For liver-directed parenteral therapies in cholangiocarcinoma and colorectal liver metastases, the hepatic arterial infusion pumps (HAIPs) are used to maximize the drug concentrations within the malignant tumors. The patency and normal functioning of the HAIP system is assessed by radionuclide imaging with 99mTc-MAA. We bring forth a relatively rare instance where the rate of infusion of the radiopharmaceutical determines the appearance of the hepatogram in the scan.

Keywords

99mTc-MAA - hepatic arterial infusion pump - liver-directed therapy


Publication History

Article published online:
05 July 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Karanicolas PJ, Metrakos P, Chan K. et al. Hepatic arterial infusion pump chemotherapy in the management of colorectal liver metastases: expert consensus statement. Curr Oncol 2014; 21 (01) e129-e136
    PubMedSearch in Google Scholar
  • 2 IJzerman NS, Filipe WF, Bruijn P. et al. Systemic exposure of floxuridine after hepatic arterial infusion pump chemotherapy with floxuridine in patients with resected colorectal liver metastases. Biomed Pharmacother 2023; 162: 114625
    PubMedSearch in Google Scholar
  • 3 Kemeny N, Huang Y, Cohen AM. et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341 (27) 2039-2048
    PubMedSearch in Google Scholar
  • 4 Kemeny NE, Niedzwiecki D, Hollis DR. et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006; 24 (09) 1395-1403
    PubMedSearch in Google Scholar
  • 5 Raphael B, Akhurst T, Rao V, Getrajdman G, Kemeny N. Hepatic arterial pump perfusion. The value of macroaggregated albumin (MAA) SPECT/CT in comparison with MAA planar and SPECT imaging. Journal of Nuclear Medicine 2007; 48: 390
    PubMedSearch in Google Scholar
  • 6 Creasy JM, Lidsky ME. ASO author reflections: implementation of a new hepatic artery infusion program for colorectal liver metastases is safe, feasible, and effective. Ann Surg Oncol 2020; 27 (13) 5096-5097
    PubMedSearch in Google Scholar
  • 7 Napier KJ, Lidsky ME, James OG, Wildman-Tobriner B. Hepatic arterial infusion pumps: What the radiologist needs to know. Radiographics 2021; 41 (03) 895-908
    PubMedSearch in Google Scholar